The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Abstract
Background Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. In this phase 2a study, we aimed to evaluate the safety and efficacy of pegbelfermin in patients with non-alcoholic steatohepatitis.Methods In this multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2a study, we recruited adults (aged 21-75 years) with a body-mass index of at least 25 kg/m 2, biopsy-confirmed non-alcoholic steatohepatitis (fibrosis stage 1-3), and a hepatic fat fraction of at least 10% when assessed by magnetic resonance imaging-proton density fat fraction. These patients were enrolled at 17 medical centres in the USA. Eligible patients were stratified by type 2 diabetes status and they were randomly assigned (1:1:1) by a computer-based system to receive subcutaneous injections of placebo once a day, 10 mg pegbelfermin once a day, or 20 mg pegbelfermin once a week, all for 16 weeks. Participants, the study team administering treatment, and investigators analysing outcomes (who were independent of the study team and had no further involvement) were masked to treatment groups. The primary outcomes were safety and the absolute change in hepatic fat fraction after 16 weeks of treatment. All patients who were randomly assigned to groups and received the study drug or placebo were included in the primary analyses. This trial was registered with ClinicalTrials.gov, number NCT02413372.Findings Between May 12, 2015, and Aug 4, 2016, 184 overweight or obese patients with non-alcoholic steatohepatitis were screened for study inclusion. Of these, 95 (52%) patients were excluded because they no longer met study criteria and 80 (43%) patients entered the placebo lead-in phase. After further exclusions, 75 (94%) patients were randomly assigned to groups, received at least one dose of treatment (25 patients to receive 10 mg pegbelfermin once a day; 24 patients to receive 20 mg pegbelfermin once a week, and 26 patients to receive placebo), and were included in the primary analysis. A prespecified interim analysis at week 8 showed a greater than expected change in the primary outcome and supported early closing of patient enrolment, since this analysis indicated that the full planned sample size was not needed. We observed a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (-6·8% vs -1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (-5·2% vs -1·3%; p=0·008) compared with the placebo group. Most adverse events were mild; the most common events were diarrhoea in eight (16%) of 49 patients treated with pegbelfermin and two (8%) of 26 patients treated with placebo and nausea in seven (14%) patients treated with pegbelfermin and two (8%) patients treated with placebo. There were no deaths, discontinuations due to adverse events, or treatment-related serious adverse events.Interpretation Treatment with subcutaneously administered pegbelfermin for 16 weeks was generally well tolerated and significantly reduced hepatic fat fraction in patients with non-alcoholic steatohepatitis. Further study of pegbelfermin is warranted in patients with non-alcoholic steatohepatitis. Additional studies that use liver biopsies would allow for the assessment of pegbelfermin's effects on liver histology. Moreover, further studies should allow assessments of the safety and effectiveness of pegbelfermin in a larger number of patients.Funding Bristol-Myers Squibb.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pegbelfermin showed a reduction in hepatic fat (measured via MRI‐PDFF) and liver transaminases over a 16‐week treatment period as well as an improved lipid profile; [53] however, no histological readouts were available which hampers applicability of the results and warrants further studies on this compound.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [53]
In the citing paper
“Pegbelfermin showed a reduction in hepatic fat (measured via MRI‐PDFF) and liver transaminases over a 16‐week treatment period as well as an improved lipid profile; [53] however, no histological readouts were available which hampers applicability of the results and warrants further studies on this compound.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [53]
In the citing paper
“all analogues consistently have a pronounced ability to decrease plasma triglyceride levels, in many cases by as much as ~70% (refs. 81,87–91).”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“two other FGF21 analogues, AKR-001 (also known as efruxifermin)88 and pegbelfermin89,90, have not been found to significantly decrease body weight in people with obesity or type 2 diabetes.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“the magnitude of the glucose-lowering effects of FGF21 analogues is clearly lower in humans than rodents81,87–91, perhaps because of differences in brown adipose tissue metabolism between species65.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“Administration of the FGF21 analogues AKR-001 (ref. 88) and pegbelfermin89 in humans with NASH results in marked absolute decreases in liver fat (up to 70%) and significant amelioration of liver fibrosis88,89.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“clinical studies in patients with obesity and type 2 diabetes have found that FGF21-analogue administration markedly induces plasma adiponectin levels81,87–89”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“PF-05231023 has been found to increase markers of bone turnover in humans81, whereas AKR-001 (ref. 88) and pegbelfermin89 have not.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationBedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,146
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,356
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,312
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Research works printed but not linked: 3
- Charles, 2016, A phase 1 study of BMS-986036 (pegylated FGF21) in healthy obese subjects, Hepatology, 64, 546A
- Krupinski, 2016, Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis, Hepatology, 64, 749A
- Leeming DJ, Nielsen MJ, Goodman Z, et al. Plasma collagen III type III (Pro-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study. NASH Biomarkers Workshop; Washington, DC, USA; May 5, 2017.
Cited by
Sorted by citations
Items 301–400 of 549
Pan, Z., Fan, J., & Eslam, M. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.007 · Cited by 16
Therapeutic approaches for non-alcoholic steatohepatitis
Gaal, L. F. V., Mertens, J., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211034300 · Cited by 15
Exploring endocrine FGFs - structures, functions and biomedical applications
Phan, P. (2024) · International Journal of Biochemistry and Molecular Biology · doi:10.62347/palk2137 · Cited by 16
Luminal polyethylene glycol solution delays the onset of preservation injury in the human intestine
Søfteland, J. M., Bagge, J., Padma, A. M., Casselbrant, A., Zhu, C., Wang, Y., Hellström, M., Olausson, M., & Oltean, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16418 · Cited by 14
Tucker, W., McClelland, R. L., Allison, M., Szklo, M., Rye, K., & Ong, K. L. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155535 · Cited by 14
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 13
El-Eshmawy, M. M. (2023) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000228 · Cited by 17
FGF21 mediating the Sex-dependent Response to Dietary Macronutrients
Sauza, K. A. S., & Ryan, K. K. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae363 · Cited by 14
FGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis
Ghanem, M., Archer, G., Justet, A., Jaillet, M., Vasarmidi, E., Mordant, P., Castier, Y., Mal, H., Cazes, A., Poté, N., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2021oc · Cited by 16
Liu, Z., Wei, S., Jiang, Y. Z., Su, W., Ma, F., Cai, G., Liu, Y., Sun, X., Lu, L., Fu, W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.003 · Cited by 15
Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis
Tincopa, M. A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.177 · Cited by 13
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
Luo, Y., Li, X., Ma, J., Abbruzzese, J. L., & Lu, W. (2021) · Cancers · doi:10.3390/cancers13040778 · Cited by 14
Self-citationThompson, K. E., Guillot, M., Graziano, M. J., Mangipudy, R. S., & Chadwick, K. D. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115673 · Cited by 14
Sinakos, E. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0704 · Cited by 16
Recent updates on targeting the molecular mediators of NAFLD
Wang, J., Wang, L., Zhang, X., Zhang, P., Cai, J., She, Z., & Li, H. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02282-4 · Cited by 13
Zhang, T., Jiang, D., Zhang, X., Chen, L., Jiang, J., Zhang, C., Li, S., & Li, Q. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01842-0 · Cited by 13
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
Update on Clinical Trials for Nonalcoholic Steatohepatitis.
Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 13
The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21
Xu, S., Liu, Z., Tian, T., Zhao, W., Wang, Z., Liu, M., Xu, M., Zhang, F., Zhang, Z., Chen, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt3142 · Cited by 13
Effects of Weight Loss on FGF-21 in Human Subjects: An Exploratory Study
Headland, M. L., Clifton, P. M., & Keogh, J. B. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16234877 · Cited by 13
Nonalcoholic Steatohepatitis Promoting Kinases
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1713115 · Cited by 13
Siemienowicz, K. J., Furmanska, K., Filis, P., Talia, C., Thomas, J. L., Fowler, P., Rae, M. T., & Duncan, W. C. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111196 · Cited by 13
Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical Trials
Siani, A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00292-2 · Cited by 14
Aggarwal, P., Noureddin, M., Harrison, S. A., Jeannin, S., & Alkhouri, N. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2032640 · Cited by 13
Self-citationPredicting NASH response with liver fat: Are we back to square one?
Wong, V. W. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.024 · Cited by 13
Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 12
Richter, M. M., Thomsen, M. N., Skytte, M. J., Kjeldsen, S. A. S., Samkani, A., Frystyk, J., Magkos, F., Holst, J. J., Madsbad, S., Krarup, T., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae008 · Cited by 13
Lin, R., Zhou, J., Sun, Q., Xin, X., Hu, Y., Zheng, M., & Feng, Q. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17889 · Cited by 12
Meroni, M., Dongiovanni, P., Tiano, F., Piciotti, R., Alisi, A., & Panera, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117608 · Cited by 13
Fibroblast growth factor 21 for non-alcoholic steatohepatitis
Wong, V. W., & Adams, L. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32165-2 · Cited by 12
Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis
Satiya, J., Snyder, H. S., Singh, S. P., & Satapathy, S. K. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-20-247 · Cited by 11
Gor, R., Siddiqui, N. A., Fernando, R. W., Nair, A. S., Illango, J., Malik, M., & Hamid, P. (2021) · Cureus · doi:10.7759/cureus.14858 · Cited by 12
Thapa, K., Grewal, A. S., Kanojia, N., Rani, L., Sharma, N., & Singh, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200121143959 · Cited by 12
Kim, K., & Kim, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072296 · Cited by 13
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Tay, P. W. L., Ng, C. H., Lin, S. Y., Chin, Y. H., Xiao, J., Lim, W. H., Lim, S. Y., Fu, C. E., Chan, K. E., Quek, J., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002042 · Cited by 12
Self-citationMia, S., Siokatas, G., Sidiropoulou, R., Hoffman, M., Fragkiadakis, K., Markopoulou, E., Elesawy, M., Roy, R., Blair, S., Kuwabara, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102125 · Cited by 11
FGF family in health and disease
Liu, X., Jing, M., Yang, Y., Jin, Q., Feng, B., Zhang, P., Niu, C., Hu, X., & Huang, Z. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00429-0 · Cited by 14
Ghanem, M., Archer, G., Crestani, B., & Mailleux, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108669 · Cited by 12
Imbalanced Skeletal Muscle Mitochondrial Proteostasis Causes Bone Loss
Jin, Z., Mao, Y., Guo, Q., Yin, Y., Kiram, A., Zhou, D., Yang, J., Zhou, Z., Xue, J., Feng, Z., et al. (2024) · Research · doi:10.34133/research.0465 · Cited by 13
Kokkorakis, M., Folkertsma, P., Forte, J. C., Wolffenbuttel, B. H. R., van Dam, S., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156047 · Cited by 13
Glyburide Regulates UCP1 Expression in Adipocytes Independent of KATP Channel Blockade
Qiu, Y., Yang, Y., Wei, Y., Liu, X., Feng, Z., Zeng, X., Chen, Y., Liu, Y., Zhao, Y., Chen, L., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101446 · Cited by 11
Endocrine FGFs and their signaling in the brain: Relevance for energy homeostasis
Zangerolamo, L., Carvalho, M. U. W. B. D., Velloso, L. A., & Barbosa, H. C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176248 · Cited by 11
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH
Fraser, D. A., Harrison, S. A., & Schuppan, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159804 · Cited by 11
Self-citationDiagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
Ganakumar, V., Halebidu, T., Goroshi, M., & Ghatnatti, V. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071231220779 · Cited by 10
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 10
Wu, D., & van de Graaf, S. F. J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116437 · Cited by 12
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Sass‐Ørum, K., Tagmose, T. M., Olsen, J., Sjölander, A., Wahlund, P., Han, D., Vegge, A., Reedtz‐Runge, S., Wang, Z., Gao, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00391 · Cited by 11
Theofilis, P., Oikonomou, E. K., Karakasis, P., Pamporis, K., Dimitriadis, K. S., Kokkou, E., Lambadiari, V., Siasos, G., Tsioufis, K. P., & Tousoulis, D. (2025) · Liver International · doi:10.1111/liv.70016 · Cited by 10
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 11
Liang, C., Li, J., Tian, B., Tian, L., Liu, Y., Li, J., Xin, L., Wang, J., Fu, C., Shi, Z., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112298 · Cited by 12
Karamfilova, V., Assyov, Y. S., Nedeva, I., Gateva, A., Ivanova, I. D., Cherkezov, N., Mateva, L., & Kamenov, Z. A. (2021) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2021.201165 · Cited by 10
New insights into the inter-organ crosstalk mediated by ChREBP
Carbinatti, T., Régnier, M., Parlati, L., Benhamed, F., & Postic, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095440 · Cited by 13
Zhu, S., Wu, Z., Wang, W., Wei, L., & Zhou, H. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02216-y · Cited by 10
Kessoku, T., Kobayashi, T., Ozaki, A., Iwaki, M., Honda, Y., Ogawa, Y., Imajo, K., Saigusa, Y., Yamamoto, K., Yamanaka, T., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037961 · Cited by 12
FGF21 negatively affects long-term female fertility in mice
Moeckli, B., Pham, T.-V., Slits, F., Latrille, S., Peloso, A., Delaune, V., Oldani, G., Lacotte, S., & Toso, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11490 · Cited by 9
Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells
Yi, Q., Yang, J., Wu, Y., Wang, Y., Cao, Q., & Wen, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204524 · Cited by 12
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 9
Research progress on the role of FGF21 in insulin resistance
Zhang, H., Zhu, R., Sun, Q., & Du, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1619462 · Cited by 10
Les nouveaux traitements de la stéatohépatite non-alcoolique
Lanthier, N. (2020) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2020.04.003 · Cited by 9
Connelly, M. A., Rivera, J. V., Guyton, J. R., Siddiqui, M. S., & Sanyal, A. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15935 · Cited by 9
Self-citationA New FGF21 Analog for the Treatment of Fatty Liver Disease
Kleinert, M., & Müller, T. D. (2020) · Diabetes · doi:10.2337/dbi20-0025 · Cited by 9
New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
Stojsavljević, S., Duvnjak, M., Virović-Jukić, L., Hrabar, D., & Duvnjak, L. S. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00057 · Cited by 9
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Yoon, I. C., & Eun, J. R. (2019) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2019.00171 · Cited by 9
Kim, D., Lee, J., Bae, I., Kim, M., Huh, Y., Choi, J., Bae, S., Choi, I. Y., Kim, H. H., & Kim, D. K. (2020) · Biologicals · doi:10.1016/j.biologicals.2020.11.005 · Cited by 9
Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next
Jin, T. (2022) · Medical Review · doi:10.1515/mr-2022-0019 · Cited by 8
Manoli, I., Sysol, J. R., Head, P. E., Epping, M. W., Gavrilova, O., Crocker, M. K., Sloan, J. L., Koutsoukos, S. A., Wang, C., Ktena, Y. P., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.174097 · Cited by 9
Fibroblast Heterogeneity in Inflammatory Bowel Disease
Ke, B.-J., Dragoni, G., & Matteoli, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313008 · Cited by 8
Fibroblast Growth Factors: Roles and Emerging Therapeutic Applications
Ternier, G., Shahzad, K., Edirisinghe, O., Okoto, P. S., Alraawi, Z., Sonnaila, S., Phan, P., Adams, P. D., & Thallapuranam, S. (2025) · Current Drug Targets · doi:10.2174/0113894501351461250301072444 · Cited by 9
Nie, Z., Xu, J., Liu, Y., Cao, Q., Qiu, X., Su, Y., & Han, S. (2025) · International Journal of Endocrinology · doi:10.1155/ije/9943228 · Cited by 8
Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6
Eckard, A. R., Hughes, H., Hagood, N. L., O’Riordan, M. A., Labbato, D. E., Kosco, J. C., Scott, S., & McComsey, G. A. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002285 · Cited by 8
Wang, L., Dong, W., Gao, H. F., Chen, C., Liang, S., Ye, X., Liu, Y., Hou, Y., Fan, L., Pan, T., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166560 · Cited by 8
Self-citationCarrascosa, J. M., Vilarrasa, E., Belinchon, I., Herranz, P., Crespo, J., Guimerá, F., & Olveira, A. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.01.004 · Cited by 8
Chege, W., Poddar, A., Samson, M. E., Almeida, C., Miller, R., Raafat, D., Fakhouri, T. H. I., Fienkeng, M., Omokaro, S. O., & Crentsil, V. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2398 · Cited by 8
Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations
Stamou, M. I., Chiu, C. J., Jadhav, S. V., Lopes, V. F., Salnikov, K. B., Plummer, L., Lippincott, M. F., Lee, H., Seminara, S. B., & Balasubramanian, R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae118 · Cited by 7
Asgharpour, A., Dinani, A. M., & Friedman, S. L. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.01.04 · Cited by 8
Araki, N., Takahashi, H., Takamori, A., Kitajima, Y., Hyogo, H., Sumida, Y., Tanaka, S., Anzai, K., Aishima, S., Chayama, K., et al. (2020) · JGH Open · doi:10.1002/jgh3.12367 · Cited by 8
Polycystic ovary syndrome and nonalcoholic fatty liver disease
Georgescu, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00007-9 · Cited by 9
Sostre‐Colón, J., Gavin, M. J., Santoleri, D., & Titchenell, P. M. (2022) · Endocrinology · doi:10.1210/endocr/bqac035 · Cited by 7
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Béliard, S., Mourre, F., & Valéro, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06100-z · Cited by 8
Taniguchi, H., Shimizu, K., Wada, S., Nirengi, S., Kataoka, H., & Higashi, A. (2020) · Journal of PHYSIOLOGICAL ANTHROPOLOGY · doi:10.1186/s40101-020-00226-w · Cited by 8
Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis
Patikorn, C., Veettil, S. K., Phisalprapa, P., Pham, T. A., Kowdley, K. V., & Chaiyakunapruk, N. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100315 · Cited by 7
Pathology and Therapeutic Significance of Fibroblast Growth Factors
Edirisinghe, O., Ternier, G., & Kumar, T. K. S. (2025) · Targets · doi:10.3390/targets3010005 · Cited by 8
Functions of FGF21 and its role in cardiac hypertrophy
Chen, L., Gao, M., Ong, S., & Gong, G. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.007 · Cited by 7
Challenges of in vitro modelling of liver fibrosis
Ros-Tárraga, P., Villanueva-Bádenas, E., Sanchez-Gonzalez, E., Ferrer, G. G., Donato, M. T., & Tolosa, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1567916 · Cited by 11
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 7
Brodosi, L., Petroni, M. L., & Marchesini, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208746 · Cited by 7
Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway
Zhou, C., Pan, X., Huang, L., Wu, T., Zhao, T., Qi, J., Wu, J., Mukondiwa, A. V., Tang, Y., Luo, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166870 · Cited by 7
Self-citationBalakrishnan, M., & Loomba, R. S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.018 · Cited by 7
Self-citationAnother Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver
Yang, R., Xu, A., & Kharitonenkov, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab686 · Cited by 7
The burn repair molecule? Evaluating FGF-21 in thermal injury – A systematic review
Niederegger, T., Schaschinger, T., Brandt, J., Knoedler, L., Knoedler, S. A., Palackic, A., Klimitz, F. J., Noll, D., Most, P., Ritterhoff, J., et al. (2025) · Burns · doi:10.1016/j.burns.2025.107785 · Cited by 6
Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
Li, S., Song, Z., Fan, C., Zhang, W., Ma, T., Li, X., Zhang, Q., Zhao, M., Yu, T., & Li, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116306 · Cited by 6
Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21
Liu, L., Ning, N., Xu, S., Chen, D., Zhou, L., Guo, Z., Liang, X., & Ye, X. (2024) · Microbial Cell Factories · doi:10.1186/s12934-024-02447-5 · Cited by 6
de Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6
Potential treatment strategy for NASH
Morris, A. W. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0162-1 · Cited by 6
Sak, J. J., Prystupa, A., Kiciński, P., Luchowska-Kocot, D., Kurys-Denis, E., & Bis-Wencel, H. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.2071 · Cited by 6
Tang, H., Li, J., Zinker, B. A., Boehm, S., Mauer, A. S., Rex‐Rabe, S., Glaser, K. J., Fronheiser, M. P., Bradstreet, T. E., Nakao, Y., et al. (2022) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28077 · Cited by 6
Self-citationTseng, C.-M. L., Balic, K., Charlton, R. W., Margalit, M., Mansbach, H., & Savić, R. M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3046 · Cited by 6
Karsdal, M. A., Hallsworth, K., Scragg, J. H., Leeming, D. J., Villesen, I. F., Avery, L., Haigh, L., Govaere, O., Wichmann, S., Taylor, G., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000254 · Cited by 6
Clearfield, E., Miller, V., Nadglowski, J. F., Barradas, K., Naber, J. A., Sanyal, A. J., Neuschwander‐Tetri, B. A., Messner, D. A., Baldyga, W., Balp, M., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1678 · Cited by 7
Self-citation
Metadata
- Authors
- Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., Luo, Y., & Christian, R.
- Affiliations
- Virginia Commonwealth University (US)
- Bristol-Myers Squibb (United States) (US)
- University of California San Diego (US)
- Pinnacle Clinical Research (US)
- Duke University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Thomas Jefferson University (US)
- Corresponding author
- Charles, Edgar D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 392
- Issue
- 10165
- Pages
- 2705-2717
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2905440332
- Cited by
- 550
- References
- 43
- Citations by year
- 2026: 40 · 2025: 52 · 2024: 87 · 2023: 82 · 2022: 76 · 2021: 83 · 2020: 91 · 2019: 36 · 2018: 1
- FWCI
- 41.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- PEGylation, nonalcoholic steatohepatitis, hepatic fat fraction, liver fibrosis, obesity, type 2 diabetes, drug safety, drug efficacy, subcutaneous injection, liver disease treatment
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Fibroblast Growth Factors, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Polyethylene Glycols, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
